目的 总结急性淋巴细胞白血病（acute lymphoblastic leukemia，ALL）患儿发生长春新碱诱导的周围神经病变（vincristine-induced peripheral neuropathy，VIPN）的特征，探讨VIPN发生的影响因素。 方法 选择2018年1月—2022年2月于贵州医科大学附属医院使用CCCG-ALL2015或CCCG-ALL2020方案治疗的1~18岁ALL患儿为研究对象，根据治疗方案中年龄对危险度分组的影响，将患儿分为1~10岁组（91例）和>10岁组（29例），并根据国家癌症研究所不良事件通用术语标准第5版，对发生的VIPN进行分级评估，比较不同组间在VIPN发生率、严重程度、类型上的差异。 结果 共纳入120例患儿，56例发生VIPN，发生率为46.7％。>10岁组患儿VIPN发生率高于1~10岁组（69％ vs 40％，P<0.05）。在发生VIPN患儿中，3级及以上VIPN 12例（21％），2级VIPN 44例（79％）。自主神经症状77例次（59.7％）、周围神经损伤42例次（32.5％）、颅神经损伤10例次（7.8％）。不同年龄、性别、危险度、治疗方案组别的VIPN严重程度及类型比较差异无统计学意义（P>0.05）。二元logistic回归分析结果显示，年龄是VIPN发生的影响因素（P<0.05）。 结论 儿童ALL患儿中，VIPN发生率较高，自主神经症状发生率最高；10岁以上患儿VIPN发生率较高。
Abstract
Objective To study the characteristics of vincristine-induced peripheral neuropathy (VIPN) in children with acute lymphoblastic leukemia (ALL) and the factors influencing the development of VIPN. Methods The children with ALL, aged 1-18 years, who were treated with CCCG-ALL2015 or CCCG-ALL2020 regimen in the Affiliated Hospital of Guizhou Medical University from January 2018 to February 2022 were enrolled as subjects. According to the influence of age on risk, the children were divided into 1-10 years group with 91 children and >10 years group with 29 children. VIPN was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (5th edition), and the incidence rate, severity, and type of VIPN were compared between different groups. Results A total of 120 children were enrolled in this study, among whom 56 (46.7%) developed VIPN. The >10 years group had a significantly higher incidence rate of VIPN than the 1-10 years group (69% vs 40%, P<0.05). Among the 56 children with VIPN, 12 (21%) had grade 3 VIPN or above, and 44 (79%) had grade 2 VIPN. There were 77 cases of autonomic nerve symptoms (59.7%), 42 cases of peripheral nerve injury (32.5%), and 10 cases of cranial nerve injury (7.8%). There were no significant differences in the severity and type of VIPN between the groups with different ages, sexes, degrees of risk, or treatment regimens (P>0.05). The results of binary logistic regression analysis showed that age is the influencing factor for the occurrence of VIPN (P>0.05). Conclusions There is a relatively high incidence rate of VIPN in children with ALL, with the highest incidence rate of autonomic nervous symptoms. The incidence of VIP in children over 10 years old is relatively high.
关键词
急性淋巴细胞白血病 /
长春新碱 /
周围神经病变 /
儿童
Key words
Acute lymphoblastic leukemia /
Vincristine /
Peripheral neuropathy /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 赵贝贝, 陈晓娟, 郭晔, 等. 两种不同方案治疗儿童急性淋巴细胞白血病骨髓复发的临床观察[J]. 中国当代儿科杂志, 2020, 22(4): 346-349. PMID: 32312373. PMCID: PMC7389689. DOI: 10.7499/j.issn.1008-8830.1908035.
2 高伟, 蒋梦影, 高莉, 等. 儿童急性淋巴细胞白血病治疗失败的相关因素分析[J]. 中国实验血液学杂志, 2021, 29(3): 661-668. PMID: 34105454. DOI: 10.19746/j.cnki.issn1009-2137.2021.03.002.
3 van de Velde ME, Kaspers GL, Abbink FCH, et al. Vincristine-induced peripheral neuropathy in children with cancer: a systematic review[J]. Crit Rev Oncol Hematol, 2017, 114: 114-130. PMID: 28477739. DOI: 10.1016/j.critrevonc.2017.04.004.
4 中国抗癌协会淋巴瘤专业委员会, 中国淋巴瘤南方协作组, 中国临床肿瘤学会抗淋巴瘤联盟. 长春碱类药物治疗恶性淋巴瘤中国专家共识[J]. 中国肿瘤临床, 2017, 44(5): 193-198. DOI: 10.3969/j.issn.1000-8179.2017.05.474.
5 任晓娟, 王玲, 张辉, 等. 长春新碱所致神经毒性机制的研究进展[J]. 中国小儿血液与肿瘤杂志, 2019, 24(4): 217-222. DOI: 10.3969/j.issn.1673-5323.2019.04.011.
6 Nazir HF, AlFutaisi A, Zacharia M, et al. Vincristine-induced neuropathy in pediatric patients with acute lymphoblastic leukemia in Oman: frequent autonomic and more severe cranial nerve involvement[J]. Pediatr Blood Cancer, 2017, 64(12): e26677. PMID: 28623857. DOI: 10.1002/pbc.26677.
7 Rosca L, Robert-Boire V, Delisle JF, et al. Carboplatin and vincristine neurotoxicity in the treatment of pediatric low-grade gliomas[J]. Pediatr Blood Cancer, 2018, 65(11): e27351. PMID: 30014595. DOI: 10.1002/pbc.27351.
8 van de Velde ME, Kaspers GJL, Abbink FCH, et al. Vincristine-induced peripheral neuropathy in pediatric oncology: a randomized controlled trial comparing push injections with one-hour infusions (the VINCA trial)[J]. Cancers (Basel), 2020, 12(12): 3745. PMID: 33322788. PMCID: PMC7764775. DOI: 10.3390/cancers12123745.
9 Nikanjam M, Sun A, Albers M, et al. Vincristine-associated neuropathy with antifungal usage: a Kaiser Northern California experience[J]. J Pediatr Hematol Oncol, 2018, 40(5): e273-e277. PMID: 29771861. PMCID: PMC6019195. DOI: 10.1097/MPH.0000000000001220.
10 曾缘缘, 许静, 张永. 三唑类抗真菌药物与长春新碱联用致神经毒性的文献分析[J]. 中南药学, 2019, 17(6): 956-959. DOI: 10.7539/j.issn.1672-2981.2019.06.037.
11 Skiles JL, Chiang C, Li CH, et al. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer[J]. Pediatr Blood Cancer, 2018, 65(3): e26854. PMID: 29115708. PMCID: PMC5766375. DOI: 10.1002/pbc.26854.
12 Gilchrist LS, Tanner LR, Ness KK. Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer[J]. Pediatr Blood Cancer, 2017, 64(1): 180-187. PMID: 27567009. DOI: 10.1002/pbc.26204.
13 Lavoie Smith EM, Li L, Chiang C, et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia[J]. J Peripher Nerv Syst, 2015, 20(1): 37-46. PMID: 25977177. PMCID: PMC4610712. DOI: 10.1111/jns.12114.
14 张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2007: 123-128.
15 Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405. PMID: 27069254. DOI: 10.1182/blood-2016-03-643544.
16 Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia[J]. JAMA, 2015, 313(8): 815-823. PMID: 25710658. PMCID: PMC4377066. DOI: 10.1001/jama.2015.0894.
17 Kayilio?lu H, Kocak U, Kan Karaer D, et al. Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population[J]. J Pediatr Hematol Oncol, 2017, 39(6): 458-462. PMID: 28697165. DOI: 10.1097/MPH.0000000000000910.
18 姜嘉悦, 崔晓光. 长春新碱诱发周围神经病变治疗的研究进展[J]. 临床与病理杂志, 2021, 41(11): 2695-2700. DOI: 10.3978/j.issn.2095-6959.2021.11.032.
19 Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials[J]. J Clin Oncol, 2016, 34(25): 3014-3022. PMID: 27325863. PMCID: PMC5012713. DOI: 10.1200/JCO.2015.66.2346.
20 Wu W, Hill SE, Nathan WJ, et al. Neuronal enhancers are hotspots for DNA single-strand break repair[J]. Nature, 2021, 593(7859): 440-444. PMID: 33767446. PMCID: PMC9827709. DOI: 10.1038/s41586-021-03468-5.
21 Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population[J]. Pharmacogenet Genomics, 2016, 26(2): 100-102. PMID: 26618658. DOI: 10.1097/FPC.0000000000000191.
22 Yildiz FG, Temucin ?M. Vincristine-induced neurotoxicity: electrophysiological features in children[J]. Neurol Res, 2016, 38(2): 124-129. PMID: 27118608. DOI: 10.1080/01616412.2016.1139321.
23 Stadelmann C, Timmler S, Barrantes-Freer A, et al. Myelin in the central nervous system: structure, function, and pathology[J]. Physiol Rev, 2019, 99(3): 1381-1431. PMID: 31066630. DOI: 10.1152/physrev.00031.2018.
24 Old EA, Nadkarni S, Grist J, et al. Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain[J]. J Clin Invest, 2014, 124(5): 2023-2036. PMID: 24743146. PMCID: PMC4001538. DOI: 10.1172/JCI71389.
25 Triarico S, Romano A, Attinà G, et al. Vincristine-induced peripheral neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment[J]. Int J Mol Sci, 2021, 22(8): 4112. PMID: 33923421. PMCID: PMC8073828. DOI: 10.3390/ijms22084112.
基金
贵州省科技厅自然科学基金（黔科合平台人才［2019］5406号）。
PDF(565 KB)
